Personalized clinical onboarding Members complete a digital intake, reviewed by clinicians
MPO, myeloperoxidase

Areas of interest include, but are not limited to: Classic antidiabetic, anti-obesity and cardioprotective effects Cardiovascular outcomes and mechanistic correlates Endothelial and vascular biology Myocardial metabolism and heart failure subtypes Novel renal and hepatoprotective actions Optimization and individualized use of existing GLP-1 receptor agonists Development of novel GLP-1 receptor agonists and multi-agonist (dual and triple) strategies Emerging extra-metabolic actions, including anti-inflammatory and neuroprotective effects Combination therapies, including co-formulations with insulin or SGLT2 inhibitors Innovative delivery systems, including non-injectable and implantable approaches Real-world comparative effectiveness, long-term safety, adherence and treatment durability This Collection welcomes original research, translational studies, and comprehensive reviews and meta-analyses that provide novel mechanistic insight or clinically relevant evidence to advance understanding of the expanding role of incretin-based therapies in cardiometabolic medicine

Dysregulation of these systems is commonly associated with organ-specific lesions in experimental models
Sleep Regulation Support Delta Sleep-Inducing Peptide, or DSIP, is widely researched for its role in promoting deep and restorative sleep